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Abstract
OBJECTIVES: Fibrosis and cancer are characterized by extracellular matrix (ECM) remodeling. The basement
membrane is mainly composed by collagen type IV and laminin. Tumstatin is a matrix metalloproteinase-9 (MMP-
9) generated matrikine of collagen type IV α3 chain. We evaluated the potential of tumstatin as a diagnostic
biomarker of lung disorders. METHODS: A monoclonal antibody was raised against the neo-epitope tumstatin. A
novel competitive enzyme-linked immunosorbent assay for detection of tumstatin (TUM), was developed and
technically characterized. Levels of TUM were measured in serum of patients with idiopathic pulmonary fibrosis
(IPF), chronic obstructive pulmonary disease (COPD), and non–small cell lung cancer (NSCLC) belonging to two
cohorts. RESULTS: The developed TUM enzyme-linked immunosorbent assay (ELISA) was technically robust. In
cohort 1, levels of TUM were significantly higher in NSCLC compared to healthy controls, IPF, and COPD (P =
0.007, P = 0.03 and P = 0.001, respectively). The area under the receiver operating characteristics (AUROC) for
separation of patients with NSCLC from healthy controls was 0.97, for separation of NSCLC and IPF patients was
0.98, and for separation of NSCLC and COPD patients was 1.0. In cohort 2, levels of TUM were also significantly
higher in patients with NSCLC compared to healthy controls (P = 0.002), and the AUROC for separation of NSCLC
and healthy controls was 0.73. CONCLUSIONS: We developed a technically robust competitive ELISA targeting
the fragment tumstatin. The level of TUM in circulation was significantly higher in patients with NSCLC compared
to patients with IPF, COPD and healthy controls. The assay provided high diagnostic accuracy in separating NSCLC
patients from other lung disorders and from healthy controls.
Translational Oncology (2018) 11, 528–534
Introduction
The extracellular cellular matrix (ECM) is the noncellular component of
all organs and tissues. Altered ECM remodeling plays a vital role in
diseases such as fibrosis and cancer [1]. The basement membrane (BM) is
a specialized ECM which functions as a scaffold for epithelial and
endothelial cells, acts as a barrier between tissues, and supports tissue
structure by maintaining epithelial and endothelial cell polarity and
function [2,3]. The BM also serves as a barrier for cancer cell invasion.
Breaching of the BM and loss of BM integrity are associated with an
invasive cancer phenotype [4]. The BM is also remodeled as part of
angiogenesis. During angiogenesis, the endothelial cells are induced to
proliferate and migrate by signaling molecules generated by the
degradation of the adjacent BM by proteolytic enzymes. BM degradation
leads in fact to exposure of protein domains (so called “cryptic sites”) or
protein fragments with either proangiogenic or antiangiogenic activity.
One of the best-described fragments is the matrikine endostatin, a known
inhibitor of angiogenesis and tumor growth [5].
The two main BM proteins are collagen type IV and laminin,
which together form a distinct network linked together by nidogen
and heparin sulfates [3,6–8]. Collagen type IV is formed by the
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combination in heterotrimers of six different α-chains (α1-6) in the
mammalian BMs [9]. The α3 chain of collagen type IV (COL4α3)
has been described to have restricted distribution across BMs and is
primarily found in the lungs and kidneys [10]. The structural role of
COL4α3 is illustrated by clinical manifestations of Alport’s
syndrome, Goodpasture’s syndrome, idiopathic pulmonary fibrosis
(IPF), and lung cancer, which are characterized by damage to
COL4α3 by either mutations, immune attacks or leaky vasculature
and altered BM composition [11–14].
Tumstatin is a 28-kDa fragment of COL4α3 that binds to
endothelial cells via the αvβ3 integrin [15]. It is a matrikine generated
by matrix metalloproteinase-9 (MMP-9) and known to keep
pathological angiogenesis and tumor growth in check [15–17].
MMP-9 is needed to cleave tumstatin from COL4α3 and function as
a protective matrikine. Lack of MMP-9 accelerates tumor growth in
MMP-9 knockout mice, while high COL4α3 expression correlates
with poor prognosis in patients with lung cancer [17,18]. This collagen
chain therefore has both protective and tumor-promoting capabilities.
Several studies have hypothesized the potential of matrikines, such
as tumstatin, as biomarkers of pathology; however, no such marker is
currently available [13,19–21].
Our hypothesis was that tumstatin is a potential biomarker for lung
disorders reflecting degradation of the BM. We therefore developed and
validated a novel neo-epitope specific competitive enzyme-linked
immunosorbent assay (ELISA) targeting tumstatin (TUM), and
measured the concentration of TUM in serum samples of patients
diagnosed with different lung disorders, including IPF, chronic
obstructive pulmonary disease (COPD), and non–small cell lung cancer
(NSCLC) and investigated its potential as a diagnostic biomarker.
Materials and Methods
All reagents used for the experiments were high-quality standards from
Sigma Aldrich (St. Louis, MO) and Merck (Whitehouse Station, NJ).
The synthetic peptides used for immunization and assay development
were purchased from American Peptide Company (Sunnyvale, CA).
Generation of Monoclonal Antibodies
The amino acid sequence 1426'PGLKGKRGDS'1436 in the human
α3 chain of type IV collagen was used for the generation of
monoclonal antibodies (mAbs). The corresponding sequence in rat
has one mismatch in position 6, and in mouse, it has a mismatch in
position 5 (Figure 1). Immunization was initiated by subcutaneous
injection of 200 μl emulsified antigen and 100 μg immunogenic
peptide (PGLKGKRGDS–GGC-KLH) in 4- to 6-week-old Balb/C
mice using Stimmune (Thermo Fisher). The immunizations were
repeated every second week until stable serum antibody titer levels
were reached. The mouse with the highest serum titer was selected for
fusion and rested for a month. Subsequently, the mouse was boosted
intravenously with 50 μg immunogenic peptide in 100 μl 0.9%NaCl
solution 3 days before isolation of the spleen for cell fusion. To
produce hybridoma cells, the mouse spleen cells were fused with SP2/
0 myeloma cells as described by Gefter et al. [22]. Subsequently, the
clones were plated into 96-well microtiter plates for further growth,
and the limiting dilution method was applied to promote monoclonal
growth. An indirect ELISA performed on streptavidin-coated plates
was used for the screening of supernatant reactivity.
PGLKGKRGDS-K-Biotin was used as screening peptide, while the
standard peptide PGLKGKRGDS was used to further test the
specificity of the clones. Supernatant was collected from the
hybridoma cells and purified using HiTrap affinity columns (GE
Healthcare Life Science, Little Chalfront, Buckinghamshire, UK)
according to manufacturer’s instructions.
Clone Characterization
Native reactivity was assessed using human serum and human
urine purchased from a commercial supplier (Valley Biomedical,
Winchester, VA). The cleavage site is localized at the N-terminal of
the sequence; therefore, the mAb was selected to specifically recognize
the standard peptide starting at the cleavage site (PGLKGKRGDS)
and not a sequence elongated or truncated of one amino acid
(IPGLKGKRGDS and GLKGKRGDS, respectively). The isotype of
the monoclonal antibody was determined using the Clonotyping
System-HRP kit, cat. 5300-05 (Southern Biotech, Birmingham, AL).
TUM ELISA
The TUM competitive ELISA procedure was as follows: 96-well
streptavidin-coated ELISA plates (Roche, cat. 11940279) were coated
with 10 ng/ml biotinylated peptide PGLKGKRGDS-K-Biotin
dissolved in assay buffer (25 mM Tris-BTB 2g. NaCl/L, pH 8.0),
100 μl/well, and incubated for 30 minutes at 20°C in the dark with
300 rpm shaking. Plates were washed five times in washing buffer
(20 mM TRIS, 50 mM NaCl, pH 7.2). Subsequently, 20 μl of
standard peptide or sample was added to appropriate wells, followed
by 100 μl of 7 ng/ml horseradish peroxidase–labeled monoclonal
antibody solution. The plates were incubated for 1 hour at 20°C with
300 rpm shaking and subsequently washed in washing buffer.
Finally, 100 μl 3,3',5,5-tetramethylbenzinidine (TMB) (Kem-En--
Tec cat. 438OH) was added and incubated for 15 minutes at 20°C
with 300 rpm shaking. To stop the enzyme reaction of TMB, 100 μl
of stopping solution (1%H2SO4) was added. The plate was analyzed
by an ELISA reader at 450 nm with 650 nm as reference (VersaMax;
Molecular Devices, Sunnyvale, CA). A standard curve was performed
by serial dilution of the standard peptide and plotted using a
four-parametric mathematical fit model. Standard concentrations
were 0, 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 ng/ml. Each plate
included five kit controls to monitor intra- and interassay variation.
All samples were measured within the range of the assay, and all
samples below lower limit of measurement range (LLMR) were
reported as the value of LLMR.
Figure 1. Sequence alignment between human, mouse, and rat tumstatin. The antibody recognizes residues from 1426 to 1436.
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Technical Evaluation
Two-fold dilutions of four human serum and human urine samples
were used to assess linearity. Linearity was calculated as a percentage
of recovery of the undiluted sample.
Antibody specificity was calculated as percentage of signal
inhibition by two-fold diluted standard peptide (PGLKGKRGDS),
elongated peptide (LPGLKGKRGDS), truncated peptide
(GLKGKRGDS), and non-sense peptide (LRSKSKKFRR). The
intra- and interassay variation was determined by 10 independent
runs of five quality controls and two kit controls run in double
determinations. Accuracy of the assay was measured in healthy
human serum/urine samples spiked with standard peptide and a
serum/urine sample with a known high TUM concentration, and
calculated as the percentage recovery of the measured value and the
expected concentration of the peptide or the serum/urine sample with
high TUM plus the concentration of the analyte in serum/urine.
Interference was measured in healthy human serum spiked with biotin
(low = 30 ng/ml, high = 90 ng/ml), hemoglobin (low = 0.155mM, high
= 0.310 mM), or lipids (low = 4.83 mM, high = 10.98 mM). The
interference was calculated as the percentage recovery of the analyte in
nonspiked serum. Furthermore, the interfering effect of human
anti-mouse antibody (HAMA) was evaluated. Five healthy human
serum samples were added to a panel of differentHAMA concentration.
These were analyzed with and without 5% Liquid II (Osteocalcin EIA
Puf-Liq by RocheDiagnostics) in the dilution buffer, which counteracts
the interference by HAMA. Salt interference was tested by measuring
salt samples with a concentration of 8.14 g/l NaCl at pH 7.0 and 8.0.
To define the concentration of TUM in the healthy population, 32
healthy human serum samples were measured, and the relation of the
marker concentration to age and gender of the sample donors was
evaluated. LLMR and upper limit of measurement range (ULMR) were
calculated based on the 10 individual standard curves from the intra-
and interassay variation. The analyte stability was determined for three
healthy human serum samples incubated at either 4 or 20°C for 2, 4,
and 24 hours. The stability of the samples was evaluated by calculating
the percentage variation from the sample kept at 20°C (0 hour sample).
Furthermore, the analyte stability was determined for three healthy
human serum samples exposed to four freeze and thaw cycles. To assess
the stability of the analyte, the percentage recovery of the analyte was
calculated from the sample that underwent only one freeze/thaw cycle.
Biological Validation of TUM
TUM was measured in serum samples from two different cohorts.
Both cohorts were obtained from the commercial vendor Proteogenex
(Culver City, CA). Samples were collected after informed consent and
approval by the local Ethics Committee and in compliance with the
Helsinki Declaration of 1975.
Cohort 1 included patients diagnosed with IPF, COPD, NSCLC and
colonoscopy-negative controls with no symptomatic or chronic disease.
Patient demographics are shown in Table 2. Cohort 2 included patients
diagnosed with NSCLC in cancer stage I, II, III, and IV together with
colonoscopy-negative controls with no symptomatic or chronic disease.
Patient demographics of this cohort can be found in Table 3.
Ethical Statement
The production of monoclonal antibodies performed in mice was
approved by the National Authority (The Animal Experiments
Inspectorate) under approval number 2013-15-2934-00956. All
animals were treated according to the guidelines for animal welfare.
Statistical Analysis
Characteristics of the cohorts are presented as a number
(frequency) and percentage for categorical variables and mean
(standard deviation) for continuous variables. Statistical differences
for categorical were assessed using a Kruskal-Wallis test (nonpara-
metric) for cohort 1 and a Mann-Whitney t test in cohort 2. Results
are shown as a Tukey boxplots. The diagnostic power of TUM was
investigated by the area under the receiver operating characteristics
(AUROC) curve. For all statistical analyses performed, a P value
below .05 was considered significant. Asterisks indicate the following:
*P b .05; **P b 0.01. Statistical analysis and graphs were performed




The best antibody producing hybridomas were screened for
reactivity towards the standard peptide and native material in the
competitive ELISA. Based on the reactivity, the clone
NBH134#102-3GF was chosen for assay developed and determined
to be the IgG1 subtype. Native reactivity was observed in human
serum and urine (Figure 2), while no reactivity was found towards the
elongated peptide, truncated peptide, non-sense standard peptide,
and non-sense coater (Figure 3).
Technical Evaluation of the TUM ELISA Assay
A full technical validation was performed to evaluate the TUM
ELISA assay. A summary of the validation data can be found in Table 1.
The measurement range (LLMR-ULMR) of the assay was determined
to be 0.26 to 9.92 ng/ml. The intra- and intervariation was 8.04% and
10.96%, respectively, based on 10 independent assays. Linearity of the
human samples was observed from undiluted to four-fold dilution for
human serum, and undiluted to two-fold dilution for human urine.
Spiking recovery of standard peptide in human serum, and human
serum in human serum resulted in a mean recovery of 90% and 99%,
respectively. Hemoglobin, lipids, and biotin did not interfere with
measurements of the TUM analyte in human serum. The stability of
Figure 2. Assay linearity. Inhibition curves for the standard peptide
and native material (human serum and human urine). The standard
peptide was two-fold diluted starting from 20 ng/ml. The samples
were tested undiluted and up to eight-fold diluted as indicated. The
data are presented as percentage (%) of background absorbance,
which is the absorbance of the assay buffer, as a function of
peptide concentration.
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the analyte was acceptable during both prolonged storage of human
serum samples at 4°C and 20°C (102.4% and 80.1%) and during
freeze/thaw cycles (80.8%).
Biological Evaluation – TUM as a Biomarker for Lung Cancer
TUM was measured in serum of patients with lung disorders from
two independent cohorts: cohort 1 and cohort 2.
Cohort 1 consists of healthy controls and patients diagnosed
with IPF, COPD, and NSCLC. TUM was significantly elevated
in serum from NSCLC compared to healthy controls, IPF patients,
and COPD patients (P = 0.007, P = 0.03, and P = 0.001,
respectively) (Figure 4). No significant difference was observed
between healthy controls, IPF patients, and COPD patients, which
indicated that TUM may play a role in NSCLC but not in fibrotic
lung disorders.
In cohort 2, TUM was measured in samples from healthy controls
and patients with NSCLC. TUM was significantly upregulated
in patients with NSCLC compared to healthy controls (P = .002)
(Figure 5). TUM was not significantly different between the different
cancer stages.
The AUROC was used to evaluate the diagnostic power of TUM
to separate NSCLC and healthy controls. As shown in Table 4, TUM
was able to discriminate between NSCLC patients and healthy
controls in cohort 1 with an AUROC of 0.97, NSCLC patients and
IPF patients with an AUROC 0.98, and NSCLC and COPD patients
with an AUROC of 1.00.
In cohort 2, TUM was able to discriminate between NSCLC
patients and healthy controls with an AUROC 0.73. We furthermore
saw that diagnostic accuracy increased with disease stage. These
findings indicate that serological TUM levels could be used to
separate healthy controls from patients with NSCLC with a high
diagnostic accuracy.
Discussion
In the present study, we developed and characterized a novel
competitive ELISA for the detection of tumstatin (TUM) using a
monoclonal antibody detecting a MMP-9 generated neo-epitope
fragment of the alpha 3-chain of collagen type IV corresponding to
the bioactive molecule tumstatin. The main findings of this study
were: i) the assay was technically robust and specific towards the
human tumstatin sequence PGLKGKRGDS, ii) the fragment was
detectable in human serum and urine and iii) the fragment was
significantly elevated in patients with NSCLC compared to IPF
patients, COPD patients, and healthy controls, with a high diagnostic
accuracy. To our knowledge, this is the first study to develop and
validate a specific biomarker of tumstatin and validate it in patients
with lung disorders.
TUM was characterized as being a technically robust and sensitive
assay, with an IC50 value of 1.6 ng/ml and measurement range from
0.26 ng/ml to 9.92 ng/ml. All technical tests including intra- and
intervariation, dilution recovery, interference, and analyte stability
gave results within the acceptable range, and the assay specificity test
showed that the monoclonal antibody was specific towards the
Figure 3. Assay specificity. Inhibition curves for to the standard
peptide (PGLKGKRGDS), the elongated peptide (LPGLKGKRGDS),
the truncated peptide (GLKGKRGDS), and a non-sense peptide
(LRSKSKKFRR) in the TUM assay. The peptides were two-fold
diluted starting from 20 ng/ml. The background signal was tested
using a non-sense coating peptide (Biotin-LRSKSKKFRR). The data
are presented as absorbance as a function of peptide
concentration.
Table 1. TUM ELISA Technical Validation Data
Technical Validation Test Result
IC50 1.6 ng/ml
Detection range 0.26-9.92 ng/ml
Intraassay variation a 8.04%
Interassay variation a 10.96%
Dilution recovery of human serum a 89%
Dilution recovery of human urine a 98%
Analyte recovery 24 h, 4°C/20°C a 102.4%/80.1%
Hemoglobin recovery, low/high a 100%/100%
Lipemia recovery, low/high a 100%/100 %
Biotin recovery, low/high a 120%/106%
Salt recovery, pH 6.0/pH 7.0/pH 8.0 b 97 %
Spiking recovery (peptide in serum) a 90%
Spiking recovery (serum in serum) a 99%
Analyte recovery, 4 freeze/thaw cycles a 80.8%
a Percentages are reported as mean.
b Average recovery after salt interference.










Age 54.88 (7.85) 74.13 (8.36) 75.38 (1.69) 60.50 (9.32) b0.001
Male, n (%) 6 (75%) 4 (57%) 4 (50%) 7 (87.5%) 0.102
BMI 26.25 (1.27) 25.79 (1.58) 27.24 (1.84) N/A 0.170
FEV1% of
predicted value
- 64.38 (3.42) 61.50 (7.19) - 0.634
FEV1/FVC ratio % - 76.00 (1.51) 58.38 (15.20) - 0.016
TUM (ng/ml) 1.79 2.00 1.58 4.24 b0.001
Data are presented as mean (SD) unless otherwise stated. Comparison of age, gender, BMI, and
TUM levels was performed using Kruskal-Wallis adjusted for Dunn’s multiple comparisons test,
while comparison of FEV1% of predicted value and FEV1/FVC ratio % was calculated using the
Mann-Whitney unpaired t test. P values below .05 were considered significant. Abbreviations:
BMI, body mass index; FEV1, forced expiratory volume in 1 second; NSCLC, non–small cell
lung cancer; FVC, forced vital capacity.
Table 3. Patient Demographics of Cohort 2
Healthy Controls (n = 20) NSCLC (n = 40) P Value
Age 61.85 (1.95) 61.93 (2.14) 0.593
Male, n (%) 10 (50%) 20 (50%) 1.000
BMI 26.14 (2.67) 25.55 (4.23) 0.533
TUM (ng/ml) 1.26 2.00 0.002
Data are presented as mean (SD) unless otherwise stated. Comparison of age, gender, BMI, and
TUM levels was performed using a Mann-Whitney t test. P values below .05 were considered
significant.
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cleavage site between amino acid 1425 and 1426 located in the alpha
3-chain of collagen type IV.
Our hypothesis was that tumstatin reflected the dysregulated
turnover of the BMs [17]. Tumstatin was originally identified by
Maeshima et al. [23] and named for its unique property of causing
“tumor stasis.” In that study tumstatin was shown to inhibit
proliferation of vascular endothelial cells and tube formation by
in vitro and in vivo models of angiogenesis and tumor growth [23],
having therefore a protective role in cancer development. Decreased
serum levels of Col. IV α3 have previously been detected in MMP-9–
deficient mice compared to normal mice [13]. This suggested that
circulating tumstatin was only present as a consequence of MMP-9–
mediated cleavage of COL4α3. Both MMP-9 and COL4α3 need to
be upregulated for tumstatin to be generated and detected in human
circulation. MMP-9 is known to be upregulated in cancer [24,25],
and this could explain why levels of TUM are elevated in serum of
patients with NSCLC. Since the fragment detected by TUM can only
be found in serum when MMP-9 generates it, our results may suggest
that NSCLC patients have a high MMP-9 activity, which increases
the expression of tumstatin [13,18]. In line with this, MMP-9–
generated type I collagen fragments have previously shown potential
as biomarkers for NSCLC [26].
In this study, we showed that TUM has a diagnostic potential for
NSCLC and is able to separate these patients from patients with lung
fibrosis. Based on the high diagnostic accuracy, this could be a
biomarker of BM remodeling in lung cancer. High levels of TUM in
circulation may indicate disruption of the BM, which can favor cancer
invasion [27]. Therefore, TUM may also serve as a marker of tumor
activity and severity. As tumstatin appeared to have an antiangiogenic
role, TUM may be used as a biomarker to assess the efficacy of
antiangiogenic therapies. Antiangiogenic therapies have been exten-
sively studied for the treatment of different cancer types including
lung cancer. Despite many of them having been approved for the
treatment of cancers, the overall survival benefit has been modest
[28]. Biomarkers such as TUM may have the potential to identify the
patients most or least likely to benefit from these drugs ‐ a current
medical need as there are no validated biomarkers for this purpose
[29]. TUM may also be applied to study the intrinsic and acquired
resistance mechanisms associated with these antiangiogenic com-
pounds. Thus, based on the present findings and previously described
role that many ECM/BM components and specific degradation
fragments have in association to the pro- or antiangiogenic activity
[17,27,30–38], TUM may have potential as a clinically relevant
biomarker for predicting response to treatment. It could furthermore
be used to study possible resistance mechanisms to anti‐angiogenic
compounds.
A limitation of the study lies in the relatively small population sizes
and in the cross-sectional design. Moreover, we had limited clinical
information on the patients. Nevertheless, we were able to confirm
the findings from cohort 1 in cohort 2. Larger longitudinal studies are
needed to fully evaluate the potential of TUM as a diagnostic and/or
prognostic biomarker for NSCLC.
The assay was evaluated to be technical robust and not interfere
with potential substances present in blood. However, whether the age
of the samples or hemodialysis interferes with the assay was not
analyzed, which is a limitation.









1.97 100 87.5 0.97 (0.89-1.05) 0.002
NSCLC vs IPF 3.67 87.5 100 0.98 (0.75-1.00) b0.0001




1.27 100 44 0.73 (0.60-0.84) 0.003
NSCLC stage IV vs
healthy controls
1.27 100 60 0.87 (0.73-1.01) 0.001
Figure 4. Results from cohort 1. Serum TUM levels was assessed
in healthy controls (n = 8) and in patients with IPF (n = 7), COPD
(n = 8), and NSCLC (n = 8). Data were analyzed using a
Kruskal-Wallis test adjusted for Dunn’s multiple comparisons
test. Data are presented as Tukey boxplots. Significance levels:
*P b 0.05 and **P b 0.01.
Figure 5. Results from cohort 2. Serum TUM levels was assessed
in healthy controls (n = 20) and in patients with NSCLC (n = 40).
Data were analyzed using a Mann-Whitney t test. Data are
presented as Tukey boxplots. Significance levels: **P b 0.01.
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In conclusion, we developed the technically robust competitive
ELISA TUM targeting a MMP-9–generated collagen type IV
alpha-3 chain fragment known as tumstatin. TUM levels were
significantly higher in serum of patients with NSCLC compared to
patients with IPF, patients with COPD, and healthy controls. The
assay provided high diagnostic accuracy in separating NSCLC
patients from those with other lung disorders and from healthy
controls. Since tumstatin acts as an inhibitor of tumor growth and
has an antiangiogenic role, the marker may be used as a marker of
angiogenesis and tumor formation.
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